Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The company is one of the most profitable companies manufacturing speciality chemicals in India
Cipla and Ethris partner for the development of mRNA-based therapies
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The product is backed by required scientific proof and comparative bioequivalence studies
The investment will enable the company to enter European markets as well as enhance margins in current markets
Subscribe To Our Newsletter & Stay Updated
